The Executive Diagnostic and Governance Toolkit
Therapeutic Platform Prioritization for Chief Scientific Officers
Score your own function red, amber or green, find out which part is weakest, and walk into the next budget round able to defend what you want to fix. Built for leaders reviewing decide which therapeutic platforms to prioritize for clinical translation this year.
Each order is checked and updated against the latest insights before delivery. That is why access takes up to 24 hours rather than being instant.
| 1 |
You stop guessing where you stand. You finish with a score, not an opinion: every part of your function rated red, amber or green, with the weakest ranked first. Evidence: a Quick Scan for the shape of it, then seven domain assessments of 30 scored questions each, 210 in all, rolled into one scorecard, plus a maturity radar and a current-versus-target gap analysis. |
| 2 |
You can defend the decision. You walk into the budget round with the gap named, the owner named and done defined, instead of a case built on instinct. Evidence: project charter, scope statement, RACI, requirements traceability and work breakdown structure, pre-filled in your domain's language. |
| 3 |
The work actually moves. The month after the decision is already built, so nothing stalls waiting for someone to design a form. Evidence: more than 60 project templates across all five PMBOK process groups, plus runbooks, SOPs, a KPI framework, audit checklists and a risk matrix. 55 to 65 files in total. |
| 4 |
You use it the day it lands. No blank templates to interpret. Every workbook opens with what it is, who uses it, when, how, a 1 to 5 scoring guide, what good looks like, and a worked example you delete and type over. |
The situation this is built for
You inherit complex data from discovery teams, face competing internal priorities, and must justify high-stakes platform bets without definitive clinical proof. The pressure to deliver transformative therapies clashes with incomplete datasets, uncertain mechanistic validation, and misaligned incentives across functions. Without a rigorous, shared framework, platform decisions become political, delayed, or reversed—wasting years and tens of millions.
Who this is for
Chief Scientific Officer in a biotechnology company leading therapeutic platform strategy and early clinical translation decisions. Responsible for integrating discovery insights, preclinical evidence, and clinical feasibility into a coherent platform portfolio. Regularly chairs or informs target nomination committees, platform steering boards, and R&D strategy reviews.
Who this is not for
This is not for lab scientists, clinical operations leads, or business development executives. It is not about licensing deals, market sizing, or regulatory strategy. It is specifically for science leaders accountable for platform-level go/no-go decisions.
What you walk away with
- A standardized framework to assess platform potential across therapeutic areas
- Clarity on which platforms to advance, deprioritize, or terminate
- Improved alignment between discovery, translational medicine, and clinical development
- Evidence-based decision memos for platform steering committees
- A defensible, auditable process for portfolio governance
How this maps to your situation
- Unclear platform definitions lead to misaligned expectations
- Inconsistent evaluation criteria result in biased decisions
- Lack of cross-functional integration delays platform decisions
- Absence of governance creates portfolio drift over time
Before vs. after
What's included with your purchase
- 12 modules with 12 chapters each (144 chapters)
- Downloadable templates and worked examples for every module
- Hand-built implementation playbook delivered alongside course access
- 30-day money-back guarantee
Delivery and format
- Course and learning environment access provisioned within 24 hours of purchase
- Hand-built implementation playbook delivered alongside course access
Format: Text-based modules and chapters in the Art of Service learning environment, plus downloadable templates and worked examples for every chapter, plus the hand-built implementation playbook delivered alongside course access.
Time investment: Approximately 45 hours of focused engagement, designed to be completed in parallel with ongoing platform reviews.
How this compares to the alternatives
Unlike generic strategy frameworks or academic reviews, this course delivers field-specific tools used in actual platform steering committees, with templates modeled on real R&D governance artifacts.
Also included: the full course, for when you want the reasoning behind a finding (12 modules, 144 chapters)
Depth reference. The diagnostic and the templates stand on their own; this is what to read when you want the reasoning behind a finding.
- Distinguishing platform from program in biologic discovery
- Mapping platform scope across modalities and targets
- Setting boundaries for platform-specific data sharing
- Identifying platform-enabling technologies and tools
- Documenting platform-specific assay development paths
- Clarifying platform ownership across research teams
- Defining platform lifecycle stages without phase language
- Aligning platform scope with organizational structure
- Tracking platform evolution over time
- Integrating platform definitions into R&D documentation
- Using platform scope to guide resource allocation
- Avoiding scope creep in early-stage platform development
- Benchmarking platform mechanisms against published literature
- Evaluating target engagement claims for novelty
- Assessing functional domain innovation in protein design
- Comparing platform output to endogenous biology
- Identifying platform-specific pharmacodynamic signatures
- Mapping platform advantages across tissue types
- Determining platform specificity in polypharmacology contexts
- Evaluating platform durability in chronic disease models
- Assessing resistance mechanisms unique to the platform
- Differentiating platform effects from background noise
- Quantifying platform signal amplification over baseline
- Using competitive intelligence to stress-test novelty
- Designing platform-specific in vitro validation cascades
- Selecting appropriate cell-based models for platform testing
- Evaluating platform performance in primary human cells
- Assessing platform stability under physiological conditions
- Validating platform delivery and biodistribution profiles
- Measuring platform persistence in relevant tissues
- Quantifying on-target versus off-target activity
- Testing platform function across donor variability
- Assessing platform immunogenicity in humanized models
- Documenting assay conditions for cross-platform comparison
- Ensuring preclinical models reflect human disease biology
- Avoiding overinterpretation of surrogate endpoints
- Aligning data timelines across functional groups
- Creating cross-functional evidence dashboards
- Weighting evidence by predictive value for translation
- Resolving contradictions between in vitro and in vivo results
- Incorporating biomarker feasibility into platform scoring
- Evaluating platform compatibility with existing CMC processes
- Assessing platform scalability from milligram to kilogram
- Factoring in formulation constraints early in evaluation
- Mapping platform-related toxicities across species
- Integrating biodistribution data into safety projections
- Using pharmacokinetic modeling to inform platform design
- Balancing potency with exposure in platform optimization
- Cataloging platform-specific failure modes in development
- Identifying dependency risks in reagent supply chains
- Assessing platform sensitivity to manufacturing variation
- Evaluating platform robustness across dose ranges
- Mapping platform-related immunogenicity concerns
- Predicting platform clearance mechanisms in humans
- Assessing platform interference with concomitant therapies
- Evaluating platform performance in comorbid models
- Documenting platform-specific assay drift risks
- Identifying platform bottlenecks in scale-up processes
- Anticipating platform-specific storage and handling issues
- Tracking platform mutation or degradation over time
- Setting minimum potency thresholds for platform progression
- Defining acceptable off-target activity limits
- Establishing platform expression duration benchmarks
- Creating biodistribution success criteria by tissue
- Setting platform-specific safety margins from toxicology
- Defining platform manufacturability pass/fail standards
- Establishing formulation stability acceptance ranges
- Creating platform-specific biomarker response targets
- Setting minimum durability requirements in disease models
- Defining platform-specific dosing frequency goals
- Establishing platform scalability milestones
- Creating decision rules for platform iteration cycles
- Assessing platform compatibility with clinical monitoring tools
- Evaluating platform dosing regimen practicality
- Mapping platform requirements to clinical site capabilities
- Assessing platform cold chain needs for global trials
- Evaluating platform administration burden on patients
- Aligning platform kinetics with disease progression rates
- Assessing platform compatibility with combination regimens
- Evaluating platform safety monitoring requirements
- Mapping platform elimination pathways for patient safety
- Assessing platform interactions with common medications
- Evaluating platform suitability for pediatric populations
- Considering platform implications for healthcare systems
- Structuring agenda for platform evaluation meetings
- Preparing decision-ready dossiers for review committees
- Presenting platform data with balanced risk communication
- Facilitating debate between discovery and development teams
- Incorporating regulatory insights into platform assessment
- Engaging manufacturing experts in early platform reviews
- Integrating clinical operations feedback on platform design
- Managing cognitive biases in group decision-making
- Documenting platform review outcomes and action items
- Creating decision trails for future audit purposes
- Following up on platform-related action items systematically
- Adjusting platform criteria based on review feedback
- Defining core metrics for platform comparison
- Weighting scorecard categories by strategic importance
- Normalizing data across different platform types
- Creating visual scorecard dashboards for leadership
- Incorporating risk-adjusted scoring methodologies
- Updating scorecards with new experimental data
- Using scorecards to identify platform optimization needs
- Benchmarking platform scores against historical programs
- Calibrating scorecard thresholds across therapeutic areas
- Training teams on consistent scorecard application
- Auditing scorecard decisions for bias and drift
- Archiving scorecards for portfolio trend analysis
- Translating platform science for non-scientific audiences
- Creating executive summaries of platform assessments
- Visualizing platform data for board-level presentations
- Communicating platform risks without technical jargon
- Justifying platform termination decisions transparently
- Explaining platform trade-offs in resource allocation
- Presenting platform portfolio balance to investors
- Aligning platform messaging across functions
- Preparing platform Q&A for due diligence scenarios
- Documenting platform decision rationale for audits
- Maintaining platform communication consistency over time
- Anticipating stakeholder questions about platform bets
- Assessing platform alignment with corporate strategy
- Evaluating platform fit within existing therapeutic focus
- Balancing platform novelty against development risk
- Mapping platform resource demands across the portfolio
- Assessing platform synergy with existing assets
- Evaluating platform potential for repurposing paths
- Identifying platform gaps in therapeutic coverage
- Prioritizing platforms based on unmet medical need
- Balancing platform bets across time horizons
- Assessing platform compatibility with partnership models
- Evaluating platform exit potential from strategic view
- Adjusting portfolio mix based on platform performance
- Defining roles in platform decision-making hierarchy
- Scheduling regular platform portfolio reviews
- Creating platform stage-gate decision templates
- Documenting platform decisions in central repository
- Establishing platform data access protocols
- Setting platform reporting requirements for teams
- Creating platform archive and retrieval procedures
- Implementing platform knowledge transfer protocols
- Auditing platform governance process effectiveness
- Updating platform criteria based on portfolio experience
- Training new leaders on platform governance standards
- Evolving platform governance with organizational growth
Frequently asked
Within 24 hours your account in the learning environment is provisioned and the tailored implementation playbook is delivered alongside it.
Thousands of organisations have bought from The Art of Service since 2000.